Clinical outcome of treatment with pemetrexed/cisplatin in patients with EGFR-mutation negative (EGFR-) metastatic non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Storozhakova, Anna E. [1 ]
Vladimirova, Liubov Yu [1 ]
Kit, Oleg Ivanovich [1 ]
机构：
[1] Rostov Sci Res Inst Oncol, Rostov Na Donu, Russia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19047
引用
收藏
页数：1
相关论文
共 50 条
  • [21] EGFR Mutation Testing in Non-Small Cell Lung Cancer
    Sriram, Krishna B.
    Francis, Santiyagu M. Savarimuthu
    Tan, Maxine E.
    Bowman, Rayleen V.
    Yang, Ian A.
    Fong, Kwun M.
    [J]. CURRENT RESPIRATORY MEDICINE REVIEWS, 2010, 6 (04) : 310 - 321
  • [22] ALK and EGFR mutation analysis in a phase II trial of cisplatin/pemetrexed in Japanese patients with advanced nonsquamous non-small cell lung cancer
    Kaburaki, Kyohei
    Ohyanagi, Fumiyoshi
    Tanimoto, Azusa
    Sakatani, Toshio
    Kawano, Yuko
    Saito, Ryota
    Yanagitani, Noriko
    Kudo, Keita
    Horiike, Atsushi
    Hagiwara, Sachiko
    Motoi, Noriko
    Takeuchi, Kengo
    Ishikawa, Yuichi
    Horai, Takeshi
    Nishio, Makoto
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] CLINICAL EXPERIENCE USE GEFITINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH A MUTATION EGFR
    Vozniy, Eduard
    Popov, Anatoly
    Galkin, Michail
    Astrakhankina, Tamara
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1214 - S1214
  • [24] FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Kazandjian, Dickran
    Blumenthal, Gideon M.
    Yuan, Weishi
    He, Kun
    Keegan, Patricia
    Pazdur, Richard
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (06) : 1307 - 1312
  • [25] Targeting β-catenin enhances the therapeutic efficacy of osimertinib in EGFR- mutant non-small cell lung cancer (NSCLC).
    Suman, Shankar
    Guan, Shu-Xiao
    Navari, Nastaran
    Arasada, Rajeswara Rao
    Carbone, David P.
    Memmott, Regan M.
    [J]. CANCER RESEARCH, 2021, 81 (13)
  • [26] Advancements in understanding cardiotoxicity of EGFR- TKIs in non-small cell lung cancer treatment and beyond
    Li, Xin
    Lin, Yongping
    Lin, Song
    Huang, Jiayi
    Ruan, Zhongbao
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [27] EGFR Mutation in Non-Small Cell Lung Cancer is Influenced by EGFR Amplification and Biomarkers
    Pollen, M.
    Waterman, J. P.
    Ding, M.
    Alvarez, A.
    Boyd, M.
    Streifel, J.
    Noroberg, M. L.
    [J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2009, 11 (06): : 655 - 655
  • [28] Osimertinib for the treatment of patients with EGFR mutation-positive non-small cell lung cancer
    Alsharedi, M.
    Bukamur, H.
    Elhamdani, A.
    [J]. DRUGS OF TODAY, 2018, 54 (06) : 369 - 379
  • [29] EGFR mutation profile in Australian patients with non-small cell lung cancer
    Mead, Scott
    Lucas, Mark
    Pang, Jia-Min
    Fellowes, Andrew
    Harraway, James
    Svobodova, Suzanne
    Amanuel, Benhur
    Fox, Stephen
    [J]. PATHOLOGY, 2021, 53 (07) : 933 - 936
  • [30] Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
    Paulina Bracht, Jillian Wilhelmina
    Karachaliou, Niki
    Berenguer, Jordi
    Pedraz-Valdunciel, Carlos
    Filipska, Martyna
    Codony-Servat, Carles
    Codony-Servat, Jordi
    Rosell, Rafael
    [J]. INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2019, 15 (12): : 2607 - 2614
12345